

THE PROBLEM



Sepsis is a life-threatening condition characterized by the body's inflammatory response to an infection. The rapid identification of the blood infection is key because if sepsis is not treated with antibiotics it can progress to severe sepsis or septic shock and can lead to multiple organ failure and death. During the first 3 hours of inpatient, less than 40% of the sepsis patients have started the antibiotic therapy, increasing 10% of the mortality rate each hour without treatment.



THE SOLUTION



SeptiLoop is a diagnostic device that analyzes the biological activity of blood immune cells identifying a previous contact with bacterial stimulus.

- The specific host response upon an infection can be detected in hours, and provide actionable clinical information in 100% of suspected sepsis cases.
- The device is able to quantify directly from whole blood specific markers from the patient's own immune system – the "host" response.

KEY BENEFITS




- PREDICTIVE** results
- FAST** Results in < 3h
- EASY WORKFLOW**
- Room temperature** storage


MILESTONES

- 2018 **Foundation**
- 2019 **Proof of Concept**
- 2019 **Patent Protection** (Application pending)
- 2019 **Clinical Validation**
- 2021 **CE Mark / Market Launch**

FUNDS RAISED



FUNDING GOALS



KEYMETRICS

- 0,6€** Production cost
- 1** Blood drops needed
- 0,3%** European population prevalence
- 2 – 3 h** Time to carry out a test
- 50 - 100€** / SeptiLoop Dx Test

ACCELERATION PROGRAMS

- IMAGINEIF (2019)**
- Bioentrepreneur Bootcamp (2018)**
- PREACCELERACIÓ Barcelona Activa (2018)**

MANAGING TEAM



Enrique Hernández, PhD



Erika P. Plata-Menchaca



Eduard Guerrero



PROMOTER

WITH THE SUPPORT OF



www.cimti.cat | info@cimti.cat

